Page 99 - 《中国药房》2024年1期

[ 4 ] ARMSTRONG A J，IGUCHI T，AZAD A A，et al. LBA25 raterone for prostate cancer not previously treated with
final overall survival （OS） analysis from ARCHES：a hormone therapy[J]. N Engl J Med，2017，377（4）：338-351.
phase Ⅲ，randomized，double-blind，placebo （PBO）-con‐ [17] SYDES M R，SPEARS M R，MASON M D，et al. Adding
trolled study of enzalutamide （ENZA） + androgen depri‐ abiraterone or docetaxel to long-term hormone therapy for
vation therapy （ADT） in men with metastatic hormone- prostate cancer：directly randomised data from the
sensitive prostate cancer （mHSPC）[J]. Ann Oncol，2021， STAMPEDE multi-arm，multi-stage platform protocol[J].
32：S1300-S1301. Ann Oncol，2018，29（5）：1235-1248.
[ 5 ] SMITH M R，HUSSAIN M，SAAD F，et al. Darolutamide [18] CHI K N，AGARWAL N，BJARTELL A，et al. Apaluta‐
and survival in metastatic，hormone-sensitive prostate can‐ mide for metastatic，castration-sensitive prostate cancer
cer[J]. N Engl J Med，2022，386（12）：1132-1142. [J]. N Engl J Med，2019，381（1）：13-24.
[ 6 ] MOHER D，LIBERATI A，TETZLAFF J，et al. Preferred [19] ARMSTRONG A J，SZMULEWITZ R Z，PETRYLAK D
reporting items for systematic reviews and meta-analyses： P，et al. ARCHES：a randomized，phase Ⅲ study of andro‐
the PRISMA statement[J]. PLoS Med，2009，6（7）： gen deprivation therapy with enzalutamide or placebo in
e1000097. men with metastatic hormone-sensitive prostate cancer[J].
[ 7 ] SHARIFI N，GULLEY J L，DAHUT W L. Androgen de‐ J Clin Oncol，2019，37（32）：2974-2986.
privation therapy for prostate cancer[J]. JAMA，2005，294 [20] DAVIS I D，MARTIN A J，STOCKLER M R，et al.
（2）：238-244. Enzalutamide with standard first-line therapy in metastatic
[ 8 ] STERNE J A C，SAVOVIĆ J，PAGE M J，et al. RoB 2：a prostate cancer[J]. N Engl J Med，2019，381（2）：121-131.
revised tool for assessing risk of bias in randomised trials [21] KYRIAKOPOULOS C E，CHEN Y H，CARDUCCI M A，
[J]. BMJ，2019，366：14898. et al. Chemohormonal therapy in metastatic hormone-
[ 9 ] DIAS S，SUTTON A J，ADES A E，et al. Evidence synthe‐ sensitive prostate cancer：long-term survival analysis of
sis for decision making 2：a generalized linear modeling the randomized phase Ⅲ E3805 CHAARTED trial[J]. J
framework for pairwise and network meta-analysis of ran‐ Clin Oncol，2018，36（11）：1080-1087.
domized controlled trials[J]. Med Decis Making，2013，33 [22] GRAVIS G，BOHER J M，JOLY F，et al. Androgen depri‐
（5）：607-617. vation therapy （ADT） plus docetaxel versus ADT alone
[10] WOODS B S，HAWKINS N，SCOTT D A. Network meta- in metastatic non-castrate prostate cancer：impact of meta‐
analysis on the log-hazard scale，combining count and ha- static burden and long-term survival analysis of the ran‐
zard ratio statistics accounting for multi-arm trials：a domized phase 3 GETUG-AFU15 trial[J]. Eur Urol，2016，
tutorial[J]. BMC Med Res Methodol，2010，10：54. 70（2）：256-262.
[11] SWEENEY C J，CHEN Y H，CARDUCCI M，et al. Che‐ [23] GRAVIS G，FIZAZI K，JOLY F，et al. Androgen-
mohormonal therapy in metastatic hormone-sensitive pro- deprivation therapy alone or with docetaxel in non-
state cancer[J]. N Engl J Med，2015，373（8）：737-746. castrate metastatic prostate cancer （GETUG-AFU 15）：a
[12] DIAS S，WELTON N J，SUTTON A J，et al. Evidence syn‐ randomised，open-label，phase 3 trial[J]. Lancet Oncol，
thesis for decision making 4：inconsistency in networks of 2013，14（2）：149-158.
evidence based on randomized controlled trials[J]. Med [24] CLARKE N W，ALI A，INGLEBY F C，et al. Addition of
Decis Making，2013，33（5）：641-656. docetaxel to hormonal therapy in low- and high-burden
[13] FIZAZI K，TRAN N，FEIN L，et al. Abiraterone plus pred‐ metastatic hormone-sensitive prostate cancer：long-term
nisone in metastatic，castration-sensitive prostate cancer survival results from the STAMPEDE trial[J]. Ann Oncol，
[J]. N Engl J Med，2017，377（4）：352-360. 2019，30（12）：1992-2003.
[14] FIZAZI K，TRAN N，FEIN L，et al. Abiraterone acetate [25] MORI K，MOSTAFAEI H，SARI MOTLAGH R，et al.
plus prednisone in patients with newly diagnosed high- Systemic therapies for metastatic hormone-sensitive pro-
risk metastatic castration-sensitive prostate cancer state cancer：network meta-analysis[J]. BJU Int，2022，129
（LATITUDE）：final overall survival analysis of a ran‐ （4）：423-433.
domised，double-blind，phase 3 trial[J]. Lancet Oncol， [26] FIZAZI K，FOULON S，CARLES J，et al. Abiraterone
2019，20（5）：686-700. plus prednisone added to androgen deprivation therapy
[15] JAMES N，RUSH H，CLARKE N，et al. 611O abiraterone and docetaxel in de novo metastatic castration-sensitive
acetate plus prednisolone for hormone-naïve prostate prostate cancer （PEACE-1）：a multicentre，open-label，
cancer （PCa）：long-term results from metastatic （M1） randomised，phase 3 study with a 2×2 factorial design[J].
patients in the STAMPEDE randomised trial Lancet，2022，399（10336）：1695-1707.
（NCT00268476）[J]. Ann Oncol，2020，31：S509. （收稿日期：2023-05-09 修回日期：2023-10-10）
[16] JAMES N D，DE BONO J S，SPEARS M R，et al. Abi‐ （编辑：刘明伟）

中国药房 2024年第35卷第1期 China Pharmacy 2024 Vol. 35 No. 1 · 89 ·